Lars brings on Tom DiLenge, President of Law for the Biotechnology Innovation Organization, to discuss the new drug pricing proposal from the Senate and how it will affect American’s going forward. The proposal will not hold insurance companies accountable and will put more pressure on patients to cover costs on their own. Dilenge stated that “Instead of eliminating distortions within the drug pricing system, this proposal could create and exacerbate perverse incentives that disadvantage patients and taxpayers.” Listen below for more
The post Is the Senate’s proposed drug pricing good for Americans? appeared first on The Lars Larson Show.